The Supreme Court ruled unanimously on Thursday, June 14, to return to the 2nd Circuit Court of Appeals a case brought in 2005 by Texas-based Animal Science Products Inc and New Jersey-based The Ranis Co Inc who accused Hebei Welcome Pharmaceutical and North China Pharmaceutical Group and other Chinese vitamin C makers of antitrust violations. A jury trial in 2013 resulted in the plaintiffs being awarded US$147 million in damages, but its ruling was overturrned by the 2nd Circuit on grounds that the court should have deferred to Chinese law as interpreted by that country’s government.
Featured News
FTC Reaches $17M Settlement With Xponential Fitness Over Franchise Violations
Mar 19, 2026 by
CPI
Trump Administration Defends Pentagon Blacklisting of AI Firm Anthropic in Court Filing
Mar 18, 2026 by
CPI
BMG Sues Anthropic Over Alleged Use of Song Lyrics in AI Training
Mar 18, 2026 by
CPI
Google Proposes New Search Controls Amid UK Competition Scrutiny
Mar 18, 2026 by
CPI
US Appeals Court Revives Whistleblower Case Against Major Drugmakers Over Pricing Program
Mar 18, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Data-Driven Competition
Mar 19, 2026 by
CPI
Data-Driven Competition: Implications For Enforcement and Merger Control
Mar 19, 2026 by
Alexandre de Corniere & Greg Taylor
From Tipping to Trustees: Why Data-Driven Markets Require Institutional Design, Not Optimization
Mar 19, 2026 by
Jens Prüfer & Paul de Bijl
Data Barriers to Entry: What We’ve Learned About Spotting Them and What We Still Don’t Know About Solutions
Mar 19, 2026 by
Bruno Carballa-Smichowski
When the Perfect Is the Enemy of the Good: Price Discrimination, Affordability, Precarity and Market Dynamism
Mar 19, 2026 by
Dan Ciuriak